Ensign Peak Advisors
PTCT icon

Ensign Peak Advisors’s PTC Therapeutics PTCT Stock Holding History

Ensign Peak Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.4M Sell
508,056
-74,262
-13% -$5.36M 0.07% 218
2026
Q1 		$39.7M Buy
582,318
+301,746
+108% +$21.4M 0.07% 212
2025
Q4 		$21.3M Sell
280,572
-8,195
-3% -$596K 0.04% 283
2025
Q3 		$17.7M Buy
288,767
+20,550
+8% +$1.07M 0.03% 333
2025
Q2 		$13.1M Sell
268,217
-6,050
-2% -$287K 0.02% 408
2025
Q1 		$14M Buy
274,267
+65,965
+32% +$3.29M 0.03% 380
2024
Q4 		$9.4M Hold
208,302
– – 0.02% 496
2024
Q3 		$7.73M Hold
208,302
– – 0.01% 522
2024
Q2 		$6.37M Buy
208,302
+180,561
+651% +$5.85M 0.01% 563
2024
Q1 		$807K Sell
27,741
-1,399
-5% -$39.2K ﹤0.01% 1457
2023
Q4 		$803K Hold
29,140
– – ﹤0.01% 1503
2023
Q3 		$653K Hold
29,140
– – ﹤0.01% 1484
2023
Q2 		$1.19M Hold
29,140
– – ﹤0.01% 1126
2023
Q1 		$1.41M Sell
29,140
-157,110
-84% -$7.18M ﹤0.01% 985
2022
Q4 		$7.11M Buy
186,250
+169,010
+980% +$7.03M 0.02% 481
2022
Q3 		$865K Buy
17,240
+1,450
+9% +$71K ﹤0.01% 1150
2022
Q2 		$633K Buy
15,790
+4,270
+37% +$150K ﹤0.01% 1340
2022
Q1 		$430K Buy
11,520
+1,520
+15% +$58.6K ﹤0.01% 1611
2021
Q4 		$398K Buy
10,000
+3,474
+53% +$133K ﹤0.01% 1710
2021
Q3 		$243K Sell
6,526
-12,042
-65% -$495K ﹤0.01% 1729
2021
Q2 		$785K Hold
18,568
– – ﹤0.01% 1497
2021
Q1 		$879K Sell
18,568
-36,757
-66% -$2.18M ﹤0.01% 1463
2020
Q4 		$3.38M Buy
55,325
+26,175
+90% +$1.54M 0.01% 776
2020
Q3 		$1.36M Buy
29,150
+22,576
+343% +$1.11M ﹤0.01% 1172
2020
Q2 		$334K Hold
6,574
– – ﹤0.01% 1525
2020
Q1 		$293K Sell
6,574
-10,224
-61% -$515K ﹤0.01% 1486
2019
Q4 		$806K Buy
+16,798
New +$714K ﹤0.01% 1405

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Ensign Peak Advisors's PTCT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its PTC Therapeutics (PTCT) stake by 13% in Q2 2026, selling an estimated $5.36M and leaving 508,056 shares worth $41.4M. The position accounts for 0.07% of the portfolio, ranked #218.

Ensign Peak Advisors first reported a position in PTCT in Q4 2019 and has held it in 27 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Ensign Peak Advisors held 508,056 shares of PTC Therapeutics worth $41.4M as of Q2 2026.
  • Ensign Peak Advisors sold 74,262 PTC Therapeutics shares in Q2 2026, an estimated $5.36M.
  • PTC Therapeutics made up 0.07% of Ensign Peak Advisors's portfolio in Q2 2026, its #218 holding.
  • Ensign Peak Advisors first reported a position in PTC Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.